Share price
4 March 2021 | 09:05am
StockMarketWire.com - Pharmaceutical company Futura Medical said it had entered into a licensing agreement with Pride Century Ventures to allow the latter to exclusively develop and commercialise the company s gel-based erectile dysfunction treatment MED3000, in China and South East Asia.
Under the collaboration, profits from sales of the drug in the region would be split 50-50.
Pride Century Ventures, a special purpose vehicle owned by Co-High Investment Management Limited, will provide funding currently estimated to be up to £4 million for development and regulatory approval of MED3000 in the region.
The company also raised up to £2 million from HT Riverwood Multi-Growth Fund from a debt and warrants offering.
TRADING UPDATES: Futura signs development deal; UKOG gets day in court
Thu, 4th Mar 2021 19:32
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Workspace Group PLC - London-based provider of service offices - Prices its first green bond, a sterling-denominated senior unsecured guaranteed green bond issuance of GBP300 million and for a term of seven years. The bonds will bear interest at a rate of 2.25% per annum. This follows a series of fixed income investor meetings which generated strong institutional demand, company adds. Following the issue of the bonds, the company s weighted average debt facility maturity will increase from 3.9 years to 4.9 years and its weighted average cost of debt will reduce to 3.6% on a pro forma basis.